Clene Inc CLNN 深 沪
已收盘 07-02 16:00:00 美东时间
6.10
-0.030
-0.49%
华盛通- 最 高6.4219
- 今 开6.20
- 成交量 3.00万股
- 最 低 6.03
- 昨 收 6.13
- 总市值 7794.77万
- 52周最高 13.50
- 市盈率 静 --
- 换手率 0.24%
- 52周最低 3.25
- 委 比 -47.06%
- 总股本 1277.83万
- 历史最高 356.40
- 量 比 0.35
- 振 幅 6.39%
- 历史最低 2.2801
- 每 手 1
- 风险率 1.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多加州富豪开始数百公里的迁徙，原因竟是这个
①美国加州拟征财富税，推动不少亿万富豪涌入内华达州太浩湖旁的因克莱恩村和水晶湾； ②太浩湖北岸因历史划界脱离加州税管，富豪们于此地居住可实现税务与生活的双重套利； ③该征税提案引发多方反对，但超级富豪们仍加速转移资产与居所。
06-10 17:31
Clene Q1 GAAP每股亏损0.69美元，营收仅1万美元
临床阶段生物制药公司Clene周四公布2026年第一季度财报。公司GAAP每股亏损0.69美元，营收仅1万美元，远低于市场预期。不过，公司在ALS药物CN...
05-14 22:45
Clene Q1 EPS $(0.69) Misses $(0.66) Estimate, Sales $15.000K Miss $35.064K Estimate
Clene (NASDAQ:CLNN) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.66) by 4.55 percent. This is a 666.67 percent decrease over losses of $(0.09) per share from the same
05-14 20:39
Clene Q1 FY26 net loss widens to $8.09 million; revenue drops 81% to $15,000
Clene Q1 FY26 net loss widens to $8.09 million; revenue drops 81% to $15,000 Clene posted a net loss of USD 8.09 million for the quarter ended March 31, 2026, widening from USD 751,000 a year earlier. Operating loss narrowed 49% to USD 2.06 million as operating expenses fell 50% to USD 2.08 million.
05-14 19:55
Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights
Clene Inc. announced its Q1 2026 financial results and updates on its CNM-Au8 programs for treating neurodegenerative diseases like ALS and MS. The company successfully completed an FDA Type C meeting and plans to submit an NDA under the accelerated approval pathway in Q3 2026. Clene also completed multiple financings totaling over $35 million and amended its debt facility to extend maturity. Despite a net loss of $8.1 million, the company expect...
05-14 12:00
Transcript: Enlight Renewable Energy Q1 2026 Earnings Conference Call
Enlight Renewable Energy (NASDAQ:ENLT) released first-quarter financial results...
05-05 21:09
Clene prices $7M registered direct offering
Clene (CLNN) and its wholly owned subsidiary, Clene Nanomedicine on Tuesday announced the pricing of an underwritten registered direct offering of 1M shares of common stock at a purchase price of $7.0...
05-05 21:03
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
Clene Advances CNM-Au8 Toward Accelerated ALS Approval
An announcement from Clene ( ($CLNN) ) is now available. On May 4, 2026, Clene ...
05-04 20:33
Clene Announces FDA Approves Propose Data To Be Capable for Submission, Review Of New Drug Application For Pathway To Treat Amyotrophic Lateral Sclerosis
Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of
05-04 20:09
